Revision as of 21:28, 21 September 2017 edit Jytdog (talk \| contribs) Extended confirmed users, Pending changes reviewers, Rollbackers 187,951 edits →Development: blatant medical marketing and WP:SYN here in Wikipedia ← Previous edit		Revision as of 21:28, 21 September 2017 edit undo Jytdog (talk \| contribs) Extended confirmed users, Pending changes reviewers, Rollbackers 187,951 edits not about this test Next edit →
Line 8: The use of the test is described in the recommendations for the non-invasive monitoring of acute heart transplant rejection in the first evidence-based clinical practice guidelines for the care of heart transplant recipients issued by the International Society of Heart and Lung Transplantation.<ref>{{cite journal \|last1=Costanzo \|first1=MR \|last2=Costanzo \|first2=MR \|last3=Dipchand \|first3=A \|last4=Starling \|first4=R \|last5=Anderson \|first5=A \|last6=Chan \|first6=M \|last7=Desai \|first7=S \|last8=Fedson \|first8=S \|last9=Fisher \|first9=P \|displayauthors=8\|title=The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients \|journal=The Journal of Heart and Lung Transplantation \|volume=29 \|issue=8 \|pages=914–56 \|year=2010 \|pmid=20643330 \|doi=10.1016/j.healun.2010.05.034}}</ref> CareDx, Inc., announced on June 3, 2014 that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock.<ref>http://xdx.com/wp-content/uploads/2014/06/20140603-CareDx-Release_vFINAL.pdf</ref> == References==

AlloMap molecular expression testing: Difference between revisions